iFAST Diagnostics Analysis
What is iFAST Diagnostics?
Rapid antimicrobial susceptibility testing technology
Location
Whiteley, United Kingdom
Employees
11-50
Founded
2022
Product Features & Capabilities
- Antimicrobial susceptibility testing
- iFAST reader for rapid results
- Minimum Inhibitory Concentration (MIC) analysis for up to 15 drugs
Use Cases
Provide results in under 3 hours for blood samples; Analyze raw urine samples in under 4 hours; Perform up to 25 tests per day per reader; Determine resistant/susceptible outputs for clinicians; Support clinical studies in hospitals
Other Considerations
Raised $6.5M in seed funding led by KHP Ventures; UK regulatory approval expected in Q4 2025; Selected for Healthcare Innovation Consortium’s AMR Innovation Programme
